

Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd

La Rochelle, January 30, 2025 (5:40 PM CEST) - Valbiotis (FR0013254851 - ALVAL, PEA-PME eligible), a French scientific research laboratory specialized in the marketing of dietary supplements scientifically proven to prevent metabolic and cardiovascular diseases and maintain optimal daily health, **announces that the market launch of Valbiotis®PRO Metabolic Health in France will take place on February 3rd, in line with the timeline previously announced (launch in February-March 2025).**

Based on the patented active substance TOTUM•63, Valbiotis®PRO Metabolic Health is an innovative dietary supplement that provides a natural, non-drug, scientifically tested, plant-based response to moderate dysglycemia, weight management and balancing altered metabolic syndrome parameters. It addresses a key public health issue: the increase in metabolic diseases, in particular in type 2 diabetes.

TOTUM•63 is an active substance patented in 58 countries that has been the subject of four clinical trials (720 people), and validated by the scientific community (17 conference papers and 7 scientific publications).

A multi-channel strategy aligned with that of Valbiotis®PRO Cholesterol

As with the launch of Valbiotis®PRO Cholesterol last May, this launch in France is backed by a multi-channel marketing strategy, promoted by an ecosystem of partners and trusted prescribers. This strategy relies on an in-house sales force of 16 Medical Promotion Officers (MPO), and is reinforced by various sales acceleration levers (presence at congresses, referencing with supplemental insurance companies, training of healthcare professionals, awareness-raising among the general public, etc.), not to mention a dedicated media plan incorporating, among other things, targeted digital marketing.

Valbiotis®PRO Metabolic Health will be available in pharmacies covering nearly 100% of French geographical territory, whether supplied directly by Valbiotis or by wholesalers/distributors. It will come in pillboxes at the recommended retail price of €22.95 (90 gel capsules) and €39.95 (180 gel capsules). The solution will also be available in doypacks on the e-commerce site <https://www.valbiotis.com/>.

Confirmation of the commercial roadmap

This second commercial launch in France will be followed by TOTUM•854 (blood pressure) in the second quarter of 2025. Afterward, the fourth active substance in Valbiotis' portfolio, TOTUM•448 (hepatic steatosis), will be launched.

About Valbiotis

Valbiotis is a French scientific research laboratory specializing in the marketing of scientifically validated dietary supplements that support optimal daily health and prevent metabolic and cardiovascular diseases. Valbiotis has adopted an innovative approach aiming to revolutionize healthcare by developing

a new class of health nutrition products designed to reduce the impact of metabolic disorders and minimize cardiovascular risk factors. This approach relies on a multi-target strategy made possible with the use of marine and terrestrial, plant-based resources. Created in 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communications /Valbiotis

Caroline Lamberti

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial Communications / Seitosei-Actifin

Marianne Py

+33 1 80 48 25 31

marianne.py@seitosei-actifin.com

Press Relations / Seitosei-Actifin

Michael Scholze

+33 1 56 88 11 14

michael.scholze@seitosei-actifin.com



Name: Valbiotis
ISIN Code: FR0013254851
Ticker Symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.